Loading…
Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics
mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely...
Saved in:
Published in: | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2024-09, Vol.16 (5), p.e1992-n/a |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33 |
container_end_page | n/a |
container_issue | 5 |
container_start_page | e1992 |
container_title | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology |
container_volume | 16 |
creator | Jiao, Xiangyu He, Xi Qin, Shugang Yin, Xiaoling Song, Tingting Duan, Xing Shi, Haixing Jiang, Shanhui Zhang, Yupei Song, Xiangrong |
description | mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics.
This article is categorized under:
Nanotechnology Approaches to Biology > Nanoscale Systems in Biology
Biology‐Inspired Nanomaterials > Lipid‐Based Structures
LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs. |
doi_str_mv | 10.1002/wnan.1992 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3112530164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120330530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33</originalsourceid><addsrcrecordid>eNp10E1LwzAYB_AgipvTg19ACl700C0vbdocx_BlMCaI4s2SponLaJuatIz56U236UEwlwTy4_88_AG4RHCMIMSTTc3rMWIMH4EhYoSFEEbo-PCOEaIDcObcGkIaURyfggFhJE5TRobgfV47_bFqXaDr1gTtSgbK2KoreatNHRgVlLrRReAnmIbbVotSup7sqGlaXemvX1s9L6f9h-WN7Lx15-BE8dLJi8M9Aq_3dy-zx3Dx9DCfTRehwBHBYYqTSFGVUE4R5qlIMC-IoNyfPC9YqhDJY4mTlCWE5rjgsVJCFJhFLC2EImQEbva5jTWfnXRtVmknZFnyWprOZQQhHBOIaOTp9R-6Np2t_XZeYUgI9NCr270S1jhnpcoaqytutxmCWV961pee9aV7e3VI7PJKFr_yp2UPJnuw0aXc_p-UvS2ny13kN6I2jUE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120330530</pqid></control><display><type>article</type><title>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Jiao, Xiangyu ; He, Xi ; Qin, Shugang ; Yin, Xiaoling ; Song, Tingting ; Duan, Xing ; Shi, Haixing ; Jiang, Shanhui ; Zhang, Yupei ; Song, Xiangrong</creator><creatorcontrib>Jiao, Xiangyu ; He, Xi ; Qin, Shugang ; Yin, Xiaoling ; Song, Tingting ; Duan, Xing ; Shi, Haixing ; Jiang, Shanhui ; Zhang, Yupei ; Song, Xiangrong</creatorcontrib><description>mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics.
This article is categorized under:
Nanotechnology Approaches to Biology > Nanoscale Systems in Biology
Biology‐Inspired Nanomaterials > Lipid‐Based Structures
LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs.</description><identifier>ISSN: 1939-5116</identifier><identifier>ISSN: 1939-0041</identifier><identifier>EISSN: 1939-0041</identifier><identifier>DOI: 10.1002/wnan.1992</identifier><identifier>PMID: 39358893</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Animals ; Cholesterol ; Clinical trials ; formulations ; Genetic disorders ; Genetic transformation ; Humans ; Infectious diseases ; lipid nanoparticles ; Lipids ; Lipids - chemistry ; Liposomes ; Medical innovations ; mRNA stability ; mRNA therapeutics ; Nanomaterials ; Nanoparticles ; Nanoparticles - chemistry ; Nanotechnology ; Polyethylene glycol ; RNA, Messenger ; Structural design ; Structural engineering</subject><ispartof>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2024-09, Vol.16 (5), p.e1992-n/a</ispartof><rights>2024 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33</cites><orcidid>0000-0002-2853-2696</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39358893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiao, Xiangyu</creatorcontrib><creatorcontrib>He, Xi</creatorcontrib><creatorcontrib>Qin, Shugang</creatorcontrib><creatorcontrib>Yin, Xiaoling</creatorcontrib><creatorcontrib>Song, Tingting</creatorcontrib><creatorcontrib>Duan, Xing</creatorcontrib><creatorcontrib>Shi, Haixing</creatorcontrib><creatorcontrib>Jiang, Shanhui</creatorcontrib><creatorcontrib>Zhang, Yupei</creatorcontrib><creatorcontrib>Song, Xiangrong</creatorcontrib><title>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</title><title>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</title><addtitle>Wiley Interdiscip Rev Nanomed Nanobiotechnol</addtitle><description>mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics.
This article is categorized under:
Nanotechnology Approaches to Biology > Nanoscale Systems in Biology
Biology‐Inspired Nanomaterials > Lipid‐Based Structures
LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs.</description><subject>Animals</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>formulations</subject><subject>Genetic disorders</subject><subject>Genetic transformation</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>lipid nanoparticles</subject><subject>Lipids</subject><subject>Lipids - chemistry</subject><subject>Liposomes</subject><subject>Medical innovations</subject><subject>mRNA stability</subject><subject>mRNA therapeutics</subject><subject>Nanomaterials</subject><subject>Nanoparticles</subject><subject>Nanoparticles - chemistry</subject><subject>Nanotechnology</subject><subject>Polyethylene glycol</subject><subject>RNA, Messenger</subject><subject>Structural design</subject><subject>Structural engineering</subject><issn>1939-5116</issn><issn>1939-0041</issn><issn>1939-0041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp10E1LwzAYB_AgipvTg19ACl700C0vbdocx_BlMCaI4s2SponLaJuatIz56U236UEwlwTy4_88_AG4RHCMIMSTTc3rMWIMH4EhYoSFEEbo-PCOEaIDcObcGkIaURyfggFhJE5TRobgfV47_bFqXaDr1gTtSgbK2KoreatNHRgVlLrRReAnmIbbVotSup7sqGlaXemvX1s9L6f9h-WN7Lx15-BE8dLJi8M9Aq_3dy-zx3Dx9DCfTRehwBHBYYqTSFGVUE4R5qlIMC-IoNyfPC9YqhDJY4mTlCWE5rjgsVJCFJhFLC2EImQEbva5jTWfnXRtVmknZFnyWprOZQQhHBOIaOTp9R-6Np2t_XZeYUgI9NCr270S1jhnpcoaqytutxmCWV961pee9aV7e3VI7PJKFr_yp2UPJnuw0aXc_p-UvS2ny13kN6I2jUE</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Jiao, Xiangyu</creator><creator>He, Xi</creator><creator>Qin, Shugang</creator><creator>Yin, Xiaoling</creator><creator>Song, Tingting</creator><creator>Duan, Xing</creator><creator>Shi, Haixing</creator><creator>Jiang, Shanhui</creator><creator>Zhang, Yupei</creator><creator>Song, Xiangrong</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2853-2696</orcidid></search><sort><creationdate>202409</creationdate><title>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</title><author>Jiao, Xiangyu ; He, Xi ; Qin, Shugang ; Yin, Xiaoling ; Song, Tingting ; Duan, Xing ; Shi, Haixing ; Jiang, Shanhui ; Zhang, Yupei ; Song, Xiangrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>formulations</topic><topic>Genetic disorders</topic><topic>Genetic transformation</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>lipid nanoparticles</topic><topic>Lipids</topic><topic>Lipids - chemistry</topic><topic>Liposomes</topic><topic>Medical innovations</topic><topic>mRNA stability</topic><topic>mRNA therapeutics</topic><topic>Nanomaterials</topic><topic>Nanoparticles</topic><topic>Nanoparticles - chemistry</topic><topic>Nanotechnology</topic><topic>Polyethylene glycol</topic><topic>RNA, Messenger</topic><topic>Structural design</topic><topic>Structural engineering</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiao, Xiangyu</creatorcontrib><creatorcontrib>He, Xi</creatorcontrib><creatorcontrib>Qin, Shugang</creatorcontrib><creatorcontrib>Yin, Xiaoling</creatorcontrib><creatorcontrib>Song, Tingting</creatorcontrib><creatorcontrib>Duan, Xing</creatorcontrib><creatorcontrib>Shi, Haixing</creatorcontrib><creatorcontrib>Jiang, Shanhui</creatorcontrib><creatorcontrib>Zhang, Yupei</creatorcontrib><creatorcontrib>Song, Xiangrong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiao, Xiangyu</au><au>He, Xi</au><au>Qin, Shugang</au><au>Yin, Xiaoling</au><au>Song, Tingting</au><au>Duan, Xing</au><au>Shi, Haixing</au><au>Jiang, Shanhui</au><au>Zhang, Yupei</au><au>Song, Xiangrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</atitle><jtitle>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</jtitle><addtitle>Wiley Interdiscip Rev Nanomed Nanobiotechnol</addtitle><date>2024-09</date><risdate>2024</risdate><volume>16</volume><issue>5</issue><spage>e1992</spage><epage>n/a</epage><pages>e1992-n/a</pages><issn>1939-5116</issn><issn>1939-0041</issn><eissn>1939-0041</eissn><abstract>mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics.
This article is categorized under:
Nanotechnology Approaches to Biology > Nanoscale Systems in Biology
Biology‐Inspired Nanomaterials > Lipid‐Based Structures
LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>39358893</pmid><doi>10.1002/wnan.1992</doi><tpages>21</tpages><orcidid>https://orcid.org/0000-0002-2853-2696</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1939-5116 |
ispartof | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2024-09, Vol.16 (5), p.e1992-n/a |
issn | 1939-5116 1939-0041 1939-0041 |
language | eng |
recordid | cdi_proquest_miscellaneous_3112530164 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Animals Cholesterol Clinical trials formulations Genetic disorders Genetic transformation Humans Infectious diseases lipid nanoparticles Lipids Lipids - chemistry Liposomes Medical innovations mRNA stability mRNA therapeutics Nanomaterials Nanoparticles Nanoparticles - chemistry Nanotechnology Polyethylene glycol RNA, Messenger Structural design Structural engineering |
title | Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A44%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20the%20formulation%20of%20lipid%20nanoparticles%20for%20the%20optimization%20of%20mRNA%20therapeutics&rft.jtitle=Wiley%20interdisciplinary%20reviews.%20Nanomedicine%20and%20nanobiotechnology&rft.au=Jiao,%20Xiangyu&rft.date=2024-09&rft.volume=16&rft.issue=5&rft.spage=e1992&rft.epage=n/a&rft.pages=e1992-n/a&rft.issn=1939-5116&rft.eissn=1939-0041&rft_id=info:doi/10.1002/wnan.1992&rft_dat=%3Cproquest_cross%3E3120330530%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3120330530&rft_id=info:pmid/39358893&rfr_iscdi=true |